James Palacino - H3 Biomedicine Inc., Cambridge, MA

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 40 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 4436: A novel antibody-enabled dual precision targeted protein stabilization (TPS2) that augments anti-tumor immune response by targeting CBL-B inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1

Joanne Lim,Anna Skaletskaya, Uttapol Permpoon, Yeonjoon Kim, S. S. Saini, Khuloud Takrouri, Zinaida Ribkovskaia, Palash Bhar,Nathan Fishkin, Dong-Jin Choi, Ji Hyun Park,James Palacino,

Cancer Researchno. 7_Supplement (2023): 4436-4436

引用0浏览0引用

A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors

Sara A. Hurvitz,Erika P. Hamilton, Alexander I. Spira,Paula R. Pohlmann,Antonio Giordano,Katherine Clifton, Barry Douglas Anderson, Sujoy Dutta, Umesh Mangipudi, Shikha Saini,James Palacino, Tina Karunaratne,

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): TPS1114-TPS1114

引用0浏览0引用

Abstract 2118: Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader

S. S. Saini, Yeonjoon Kim,Wesley P. Wong, Tina Karunaratne, Olaf Christensen, Sandeep Dutta, Palash Bhar, Khuloud Takrouri,Nathan Fishkin, Dong-Jin Choi, Min‐Soo Kim, Joanne Lim,

Cancer Researchno. 7_Supplement (2023): 2118-2118

引用0浏览0引用

ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML